Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 280B (ZNF280B) is a member of the C2H2-type zinc finger transcription factor family, characterized by multiple zinc finger domains that facilitate DNA binding and regulation of gene expression[1][5]. As a transcription factor, ZNF280B is implicated in regulating cell proliferation and survival, especially in cancer contexts such as prostate and gastric cancers[1][2][3]. In prostate cancer, ZNF280B promotes tumor growth by up-regulating the expression of the Mdm2 gene, which in turn leads to degradation of the tumor suppressor protein p53 via enhanced proteasomal degradation—a key pro-survival and pro-growth mechanism in tumorigenesis[1]. In gastric cancer, increased ZNF280B expression is associated with larger tumor size, advanced stage, and increased proliferation, suggesting an oncogenic function[2][3]. The protein's exact mechanisms and broader physiological roles remain under investigation, but its effect on the Mdm2-p53 axis and correlation with cancer progression support its identification as a molecular target in oncology research[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 280B (ZNF280B).